journal article·2023-02-14Open access

Graphene Oxide Nanosheets Reduce Astrocyte Reactivity to Inflammation and Ameliorate Experimental Autoimmune Encephalomyelitis

Giuseppe Di Mauro, Roberta Amoriello, Neus Lozano, Alberto Carnasciali, Daniele Guasti, Maurizio Becucci, Giada Cellot, Kostas Kostarelos, Clara Ballerini, Laura Ballerini

ACS Nano· Volume 17· Issue 3

Abstract

High Resolution Image Download MS PowerPoint Slide In neuroinflammation, astrocytes play multifaceted roles that regulate the neuronal environment. Astrocytes sense and respond to pro-inflammatory cytokines (CKs) and, by a repertoire of intracellular Ca 2+ signaling, contribute to disease progression. Therapeutic approaches wish to reduce the overactivation in Ca 2+ signaling in inflammatory-reactive astrocytes to restore dysregulated cellular changes. Cell-targeting therapeutics might take advantage by the use of nanomaterial-multifunctional platforms such as graphene oxide (GO). GO biomedical applications in the nervous system involve therapeutic delivery and sensing, and GO flakes were shown to enable interfacing of neuronal and glial membrane dynamics. We exploit organotypic spinal cord cultures and optical imaging to explore Ca 2+ changes in astrocytes, and we report, when spinal tissue is exposed to CKs, neuroinflammatory-associated modulation of resident glia. We show the efficacy of GO to revert these dynamic changes in astrocytic reactivity to CKs, and we translate this potential in an animal model of immune-mediated neuroinflammatory disease.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Graphene and Nanomaterials Applications · Phagocytosis and Immune Regulation · Mesenchymal stem cell research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

International School for Advanced Studies (SISSA/ISAS), 34136Trieste, Italy

Dipartimento di Medicina Sperimentale e Clinica, University of Florence, 50139Florence, Italy

Catalan Institute of Nanoscience and Nanotechnology (ICN2), 08193Barcelona, Spain

Dipartimento di Chimica “Ugo Schiff”, DICUS, University of Florence, 50139Florence, Italy

Nanomedicine Lab, and Faculty of Biology, Medicine & Health, The National Graphene Institute, University of Manchester, ManchesterM13 9PL, United Kingdom

Funding

H2020 Future and Emerging Technologies · Generalitat de Catalunya · Agencia Estatal de Investigaci?n,Ministerio de Ciencia, Innovaci?n y Universidades

References (82)

Show source-provided references
1. 10.1038/s41582-019-0227-810.1038/s41582-019-0227-8 ↗
2. 10.1016/j.nbd.2009.11.00410.1016/j.nbd.2009.11.004 ↗
3. 10.2174/138161282266616121415310810.2174/1381612822666161214153108 ↗
4. 10.1038/s41582-020-00435-y10.1038/s41582-020-00435-y ↗
5. 10.1186/s12974-019-1516-210.1186/s12974-019-1516-2 ↗
6. 10.3389/fnins.2019.0117810.3389/fnins.2019.01178 ↗
7. 10.1038/nrn.2018.1910.1038/nrn.2018.19 ↗
8. 10.3389/fphys.2014.0006310.3389/fphys.2014.00063 ↗
9. 10.3389/fncel.2020.0020910.3389/fncel.2020.00209 ↗
10. 10.1517/14728222.9.5.88710.1517/14728222.9.5.887 ↗
11. 10.1016/j.mattod.2013.09.00410.1016/j.mattod.2013.09.004 ↗
12. 10.1126/science.124673610.1126/science.1246736 ↗
13. 10.3389/fnsys.2019.0002610.3389/fnsys.2019.00026 ↗
14. 10.3390/ijms22231304710.3390/ijms222313047 ↗
15. 10.1016/j.msec.2018.01.00410.1016/j.msec.2018.01.004 ↗
16. 10.1038/s41598-021-88760-010.1038/s41598-021-88760-0 ↗
17. 10.1038/s41390-021-01681-610.1038/s41390-021-01681-6 ↗
18. 10.1021/acs.nanolett.8b0490310.1021/acs.nanolett.8b04903 ↗
19. 10.1039/C9NH00777F10.1039/C9NH00777F ↗
20. 10.1016/j.carbon.2021.01.14210.1016/j.carbon.2021.01.142 ↗
21. 10.1016/j.biomaterials.2021.12074910.1016/j.biomaterials.2021.120749 ↗
22. 10.1039/D0NR07824G10.1039/D0NR07824G ↗
23. 10.1016/j.neuroscience.2003.07.00610.1016/j.neuroscience.2003.07.006 ↗
24. 10.1523/JNEUROSCI.4035-06.200710.1523/JNEUROSCI.4035-06.2007 ↗
25. 10.1186/s13041-021-00868-610.1186/s13041-021-00868-6 ↗
26. 10.1186/s12974-019-1519-z10.1186/s12974-019-1519-z ↗
27. 10.1186/s13041-018-0347-x10.1186/s13041-018-0347-x ↗
28. 10.1111/j.1471-4159.2008.05315.x10.1111/j.1471-4159.2008.05315.x ↗
29. 10.1016/j.neuroscience.2015.06.03810.1016/j.neuroscience.2015.06.038 ↗
30. 10.1038/nri219010.1038/nri2190 ↗
31. 10.1007/978-1-0716-1311-5_2710.1007/978-1-0716-1311-5_27 ↗
32. 10.1088/2053-1583/aac05c10.1088/2053-1583/aac05c ↗
33. 10.1021/acsnano.6b0013010.1021/acsnano.6b00130 ↗
34. 10.1016/j.nano.2020.10217410.1016/j.nano.2020.102174 ↗
35. 10.1021/acsnano.7b0773410.1021/acsnano.7b07734 ↗
36. 10.1002/advs.20190320010.1002/advs.201903200 ↗
37. 10.1002/advs.20210455910.1002/advs.202104559 ↗
38. 10.1016/j.tins.2005.12.00510.1016/j.tins.2005.12.005 ↗
39. 10.1016/j.bbi.2013.02.00510.1016/j.bbi.2013.02.005 ↗
40. 10.1016/j.mcn.2012.10.00810.1016/j.mcn.2012.10.008 ↗
41. 10.1016/0166-2236(96)10048-510.1016/0166-2236(96)10048-5 ↗
42. 10.3389/fncel.2017.0042710.3389/fncel.2017.00427 ↗
43. 10.1523/JNEUROSCI.14-03-01563.199410.1523/JNEUROSCI.14-03-01563.1994 ↗
44. 10.1523/JNEUROSCI.20-04-01435.200010.1523/JNEUROSCI.20-04-01435.2000 ↗
45. 10.1016/j.ceca.2006.07.00610.1016/j.ceca.2006.07.006 ↗
46. 10.1113/JP27238210.1113/JP272382 ↗
47. 10.1074/jbc.M10990220010.1074/jbc.M109902200 ↗
48. 10.1096/fj.05-4297fje10.1096/fj.05-4297fje ↗
49. 10.1016/j.cardiores.2003.07.00410.1016/j.cardiores.2003.07.004 ↗
50. 10.1038/npp.2011.31910.1038/npp.2011.319 ↗
51. 10.1016/j.neuropharm.2013.03.02010.1016/j.neuropharm.2013.03.020 ↗
52. 10.1016/B978-0-12-800763-1.00011-710.1016/B978-0-12-800763-1.00011-7 ↗
53. 10.1016/j.expneurol.2009.10.00910.1016/j.expneurol.2009.10.009 ↗
54. 10.1007/s11481-015-9588-y10.1007/s11481-015-9588-y ↗
55. 10.1016/j.jneuroim.2010.08.01110.1016/j.jneuroim.2010.08.011 ↗
56. 10.3389/fimmu.2016.0050610.3389/fimmu.2016.00506 ↗
57. 10.1038/nrneurol.2015.22210.1038/nrneurol.2015.222 ↗
58. 10.1016/j.jaut.2017.06.00510.1016/j.jaut.2017.06.005 ↗
59. 10.3389/fnsys.2019.0000110.3389/fnsys.2019.00001 ↗
60. 10.1016/j.chempr.2016.06.01910.1016/j.chempr.2016.06.019 ↗
61. 10.1002/glia.2092610.1002/glia.20926 ↗
62. 10.1111/j.1471-4159.2011.07210.x10.1111/j.1471-4159.2011.07210.x ↗
63. 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q ↗
64. 10.3390/ijms2004099610.3390/ijms20040996 ↗
65. 10.1523/JNEUROSCI.3794-09.200910.1523/JNEUROSCI.3794-09.2009 ↗
66. 10.3389/fphar.2021.68393510.3389/fphar.2021.683935 ↗
67. 10.1073/pnas.201645111710.1073/pnas.2016451117 ↗
68. 10.1021/acs.molpharmaceut.1c0089210.1021/acs.molpharmaceut.1c00892 ↗
69. 10.1016/j.addr.2019.07.00610.1016/j.addr.2019.07.006 ↗
70. 10.1016/j.canlet.2011.12.02510.1016/j.canlet.2011.12.025 ↗
71. 10.3390/pharmaceutics1103010110.3390/pharmaceutics11030101 ↗
72. 10.1073/pnas.171603211510.1073/pnas.1716032115 ↗
73. 10.1002/glia.2395410.1002/glia.23954 ↗
74. 10.1039/C5SC00114E10.1039/C5SC00114E ↗
75. 10.1021/acsnano.0c0343810.1021/acsnano.0c03438 ↗
76. 10.1039/D0NR03675G10.1039/D0NR03675G ↗
77. 10.1039/C7NR03552G10.1039/C7NR03552G ↗
78. 10.1002/adhm.20120024810.1002/adhm.201200248 ↗
79. 10.1371/journal.pone.016681610.1371/journal.pone.0166816 ↗
80. 10.1111/j.1469-7793.1999.0459t.x10.1111/j.1469-7793.1999.0459t.x ↗
81. 10.1111/j.1469-7793.2000.t01-1-00639.x10.1111/j.1469-7793.2000.t01-1-00639.x ↗
82. 10.1002/eji.20197010710.1002/eji.201970107 ↗